A biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases, with a focus on products used by physician specialists or in hospital settings.
The best Bull and Bear pitches based on recency and number of recommendations.
NO SOLID PHASE 3 TRIALS.HAVE MANY FAILURES IN THE PIPELINE; ALOT OF COMPETETION FOR HEP C, INCLUDING INGENIX AND SCHERING WITH PROTEASE INHIBITORS COMING OUT. NEED NEW BLOOD COARSING THROUGH ITS VEINS OR COULD SETTLE IN AT 11-13.
Read the most recent pitches from players about VPHM.DL.
Find the members with the highest scoring picks in VPHM.DL.
See what the Wall Street professionals think, according to their public statements and filings.